The Board of Directors of ScandiBio Therapeutics has, in accordance with the issue authorization granted by the extraordinary general meeting on May 15, 2020, carried out a directed share issue raising 5 million SEK. The directed share issue was carried out to strengthen the Company’s financial position going forward with human clinical trials for several indications based on the proprietary Combined Metabolic Cofactors Supplementation (CMCS).
